Singapore: Global medtech giant, Medtronic, has acquired Netherland-based Sapiens Steering Brain Stimulation (Sapiens SBS), developer of deep brain stimulation (DBS) technologies for approximately USD200 million in an all-cash transaction.

The acquisition of Sapiens SBS is intended to supplement Medtronic's capabilities in modulation of brain function.

Sapiens SBS is developing a DBS system that features an advanced DBS lead with 40 individual stimulation points. This advanced system is designed to allow more precise stimulation of the intended target in the brain and may potentially result in reduced procedure time and fewer stimulation-induced side effects.

Employees at the Eindhoven facility will continue to work toward bringing this technology to market. In the future, the site will serve as a global research and development center for Medtronic's Neuromodulation business, complementing our existing R&D operations.

Medtronic and Sapiens SBS will work to finalize product development and begin clinical research to integrate these technologies into an expanded portfolio of DBS products within Medtronic's Neuromodulation business.

"This acquisition broadens our neuroscience leadership position with innovative brain modulation technology that, along with our comprehensive portfolio of DBS solutions, may one day transform the way physicians are able to treat patients with neurodegenerative diseases like Parkinson's disease and essential tremor," said Dr Lothar Krinke, vice president and general manager of the Brain Modulation business at Medtronic.

"Since 2011, Sapiens SBS employees have worked tirelessly to develop an advanced deep brain stimulation system," said Mr Jan Keltjens, chief executive officer at Sapiens SBS. "We are excited to join Medtronic, and look forward to collectively working to bring this and other novel technologies and therapies to neuromodulation patients worldwide that could benefit from them."